JNJ-40346527 (Edicotinib)

TargetCSF1R

Modalitysmall molecule inhibitor

IndicationAlzheimer's disease

PhasePhase 1 (Terminated)

PartnerUniversity of Oxford

Trial IDNCT04121208

Notes

Edicotinib blocks the CSF1R receptor, which is essential for microglial survival. The Oxford MACS trial attempted to use this transiently in AD patients to ablate senescent microglia, but the trial was terminated early.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: June 3, 2026